Trials / Completed
CompletedNCT00189813
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Potential Efficacy, Safety and Tolerability of Different Oral Doses of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 691 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM060 |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2005-12-01
- Completion
- 2005-12-01
- First posted
- 2005-09-19
- Last updated
- 2014-08-28
Locations
45 sites across 8 countries: Bulgaria, Czechia, Estonia, Germany, Lithuania, Poland, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00189813. Inclusion in this directory is not an endorsement.